ASND1N Stock Chart & Stats
$4280.00
$0.00(0.00%)
At close: 4:00 PM EDT
$4280.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3,131.06 - $4,326.49
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$263.52B
Enterprise Value$15.13K
Total Cash (Recent Filing)$573.42M
Total Debt (Recent Filing)$897.60M
Price to Earnings (P/E)25.8
Beta0.03
Next Earnings
Aug 06, 2026EPS Estimate
29.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.19
Shares Outstanding62,376,846
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,385.54Price Target Upside25.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)242.56
Revenue Forecast (FY)$23.20B
ASND1N FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $3131.06 and its highest was $4326.49 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $263.52B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Aug 06, 2026 which is tomorrow.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on May 07, 2026. The company reported $193.995 earnings per share for the quarter, beating the consensus estimate of $3.223 by $190.772.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is 29.79.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 62,376,846 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of $193.995 in its last earnings report, beating expectations of $3.223. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in MX:ASND1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5,385.54 (25.83% Upside)
$5,385.54 (25.83% Upside)
Blogger Sentiment
Neutral
MX:ASND1N Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $75.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
101.31%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
ASND1N Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and financial achievements—rapid revenue generation (EUR 247M Q1), robust YORVIPATH adoption (>1,000 new U.S. patients in the quarter; >6,300 cumulative), YUVIWEL FDA approval with early prescriptions, solid non-IFRS profitability and a healthy cash position augmented by a USD 187.5M PRV sale—supporting a growth and commercialization narrative. Offsetting items include one-time EUR 15M Q1 headwinds, elevated noncash finance expense (EUR 63M), GAAP net profit driven by a large deferred tax asset, rising SG&A, an R&D decline influenced by an inventory write-up, and the discontinuation of an internal oncology program. Overall, positives around product approvals, commercial traction, pipeline data (notably the COACH combo), and balance sheet actions outweigh the listed lowlights, though some one-time accounting and legal/operational uncertainties temper near-term clarity.View all MX:ASND1N earnings summariesASND1N Stock 12 Month Forecast
Average Price Target
$5,385.54
▲(25.83% Upside)









